“Patients have reported high levels of satisfaction with minimal side effects. I believe the ClearView will be an excellent option for refractive lens surgeons to offer their patients seeking their best vision and independence from glasses after cataract surgery. No patients in the study reported negative dysphotopsia and reported a 94% rate of spectacle independence.”
Jeff Whitsett, MD – Houston, TX
The first U.S. commercial implantation of the newly FDA approved ClearView 3 Multifocal Intraocular lens (MIOL), was performed by Jeff Whitsett, MD of Whitsett Vision (Houston, TX).
